Abstract
Aim: Bile acids (BA) are potent signaling molecules that, through activation of nuclear receptor, farnesoid X receptor (FXR) and the membrane G protein-coupled receptor TGR5 modulate BA homeostasis, inflammation, and lipid and glucose metabolism. It has recently showed that pharmacological dual activation TGR5 and FXR plays significant role in prevention of atherosclerosis progression and this activation of BA receptors may be promising targets for treatment of both liver and metabolic disease. Total parenteral nutrition (TPN) administration is strongly associated with chronic inflammation and disturbances in BA metabolism in patients. We tested hypothesis that basal and pro-inflammatory activated status of circulating monocytes in parenteral nutrition-associated liver disease (PNALD) could be affected by BA receptor (FXR/TGR5) agonist (INT-767).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
